Item 7.01. Regulation FD Disclosure

On October 16, 2006, NovaDel Pharma Inc., a Delaware corporation (the “Company”), issued a press release to announce that the Company would present at the BIO InvestorForum 2006 Conference on October 19, 2006, in San Francisco, California. Dr. Jan Egberts, the Company’s President and Chief Executive Officer, will present a corporate overview describing the Company, including an update on the Company’s product pipeline. A copy of the Corporate Presentation which is the basis of Dr. Egberts’ October 19, 2006 presentation is attached hereto as Exhibit 99.1 and the full text of the press release is attached hereto as Exhibit 99.2. The Corporate Presentation is available on the Company’s website at www.novadel.com.

The information furnished pursuant to this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events

The Company now estimates its product candidates are expected to reach the market during the following calendar years: Zensana, 2007; NitroMist, 2007; Zolpidem, 2008; Sumatriptan, 2009; Tizanidine, 2009; and Ropinirole, 2009.

Additionally, on May 26, 2006, the Company announced that the Food and Drug Administration (the “FDA”) had accepted its submission regarding the New Drug Application for the Company’s product candidate NitroMist as a complete response and, further, that the FDA indicated a target date of early November 2006 for action on the submission. The Company is now providing additional information that the FDA has indicated a target date of November 3, 2006 for action on the submission.

The Company is also providing additional information on planned pivotal studies for zolpidem oral spray and planned clinical studies for sumatriptan oral spray, including (1) a planned definitive pharmacokinetic study for zolpidem oral spray which is designed as a 4-arm crossover study in 32 healthy volunteers using 5 and 10 mg doses of zolpidem oral spray and Ambien® tablet to begin in January 2007 and a planned geriatric pharmacokinetic 2-arm crossover study in 16 healthy volunteers using 5 mg does of zolpidem oral spray and Ambien® tablet (the key endpoints for the planned zolpidem studies are area-under-the-curve (AUC), maximum drug concentration (Cmax), time to maximum drug concentration (Tmax) and other pharmacokinetic parameters); and (2) planned clinical studies for sumatriptan oral spray which includes a pilot efficacy study in 28 migraine sufferers which began in mid-August 2006 in India and is expected to be completed in December 2006 (the key parameters are time to substantial pain relief and percent of subjects experiencing substantial pain relief at 2 hours post-dosing) and one definitive pharmacokinetic study which is tentatively designed as a 5-arm crossover study in 32 healthy volunteers using 6 mg subcutaneous Imitrex®, 50 mg Imitrex® tablet, 5 mg nasal spray, 20 mg and 30 mg doses of sumatriptan oral spray (the key endpoints are the same as described above for the zolpidem pharmacokinetic studies).

The Company is updating its patent disclosure to reflect its current patent portfolio of 8 U.S. patents issued, 51 European patents issued, and 1 Canadian patent issued and over 80 applications pending in the U.S. and overseas.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.